Results from VERITAC-2 trial showed that the proteolysis-targeting chimera (PROTAC) vepdegestrant could extend progression-free survival for people with previously treated estrogen receptor (ER)-posit...
Results from an international phase III study showed that the targeted therapy combination of encorafenib and cetuximab with mFOLFOX6 (leucovorin, fluorouracil, and oxaliplatin) chemotherapy may help ...
A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortal...
Inhaling wildfire-related air pollution may reduce the likelihood of survival among patients with non–small cell lung cancer (NSCLC), according to new findings presented by Singhal et al at the 2025 A...
Treatment options for aggressive-variant prostate cancer are limited, but a subset of patients have had promising long-term responses with a combination of carboplatin plus cabazitaxel chemotherapy, f...
Patients with leiomyosarcoma experience a high risk of recurrence and have limited treatment options. No biomarkers or targetable mutations currently improve diagnosis, prognosis, or treatment. Spatia...
Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) often experience temporary responses to current treatments, such as hypomethylating agents, which l...
For patients with metastatic clear cell renal cell carcinoma who did not benefit from checkpoint and tyrosine kinase inhibitors, limited alternative treatment options are available. ALLO-316 is a nove...
Universal germline testing is essential for identifying hereditary cancer risk, especially for patients with young-onset colorectal cancer who were diagnosed before the age of 50. However, the impleme...